Arrowhead Pharmaceuticals, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended September 30, 2019. The filing also presents unaudited fourth-quarter results. Arrowhead is a clinical-stage RNA interference therapeutics developer with no approved products or commercial product sales; revenue primarily reflects licensing and collaboration arrangements.
Financial results and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $168.8 million | $16.1 million |
| Operating income (loss) | $61.2 million | $(55.9) million |
| Net income (loss) | $68.0 million | $(54.5) million |
| Diluted earnings (loss) per share | $0.69 | $(0.65) |
| Research and development expense | $81.0 million | $53.0 million |
| General and administrative expense | $26.6 million | $19.1 million |
| Cash from (used in) operating activities | $173.0 million | $(47.2) million |
FY2019 revenue included approximately $167.5 million recognized against the Janssen ARO-HBV license and related services performance obligation, plus $1.0 million for work on the ARO-JNJ1 collaboration. The filing reports no product-sales revenue; product gross margin is therefore not meaningful. Profitability in FY2019 was driven primarily by partner transaction revenue, not recurring product operations.
At September 30, 2019, cash and cash equivalents were $221.8 million, short-term investments $36.9 million, and long-term investments $44.2 million, totaling approximately $303.0 million in cash and investments. Total assets were $349.8 million and stockholders’ equity was $244.0 million. The balance sheet showed no note payable or long-term debt; the Madison facility note had been paid off. Management said available resources were sufficient to fund operations for at least 12 months.
Operating cash flow reflected partner-related receipts and a substantial increase in deferred revenue, partly offset by approximately $66.5 million of operating expenses paid in cash. Investing cash outflow was $47.7 million and financing cash inflow was $66.4 million. Contractual obligations totaled $91.3 million, including $60.2 million of purchase commitments and $22.4 million of operating lease payments. The filing provides no conventional operating margin guidance; reported operating income reflects collaboration revenue.
Material changes and business developments
- Janssen-related revenue, including the $175 million upfront payment, a $75 million JJDC equity investment, and two $25 million development milestones, drove the sharp revenue and earnings improvement. The company recognized revenue over time for its combined ARO-HBV license and remaining R&D services; $82.8 million remained deferred at year-end.
- R&D expense rose 53% to $81.0 million as ARO-ANG3 and ARO-APOC3 entered clinical testing and ARO-AAT advanced. Clinical trial expense increased to $13.7 million from $2.9 million; drug manufacturing and toxicity/efficacy costs also increased. Management expects R&D spending to rise as more candidates advance.
- FY2019 fourth-quarter revenue was $43.3 million, operating income $9.6 million, and net income $11.7 million, or $0.12 diluted per share. In Q4 FY2018, revenue was $11.3 million and net loss was $10.8 million, or $0.12 diluted per share.
- ARO-AAT advanced into a potentially pivotal Phase 2/3 study and received FDA Fast Track designation. Phase 1 data reported substantial reductions in serum AAT, but clinical benefit and disease modification remain to be established.
- Phase 1 results for ARO-APOC3 and ARO-ANG3 showed reductions in their respective targets and blood lipids, without drug-related serious or severe adverse events reported in the summarized data. These are early, limited clinical results, not proof of clinical benefit.
- Amgen continued Phase 1 development of AMG 890 (ARO-LPA). Amgen declined its option for ARO-AMG1 in 2019, ending the prospect of further milestones or royalties for that program.
Outlook, risks and unusual items
Management’s stated near-term outlook was that liquidity should fund operations for at least 12 months. The company anticipated higher R&D costs as programs progressed and planned clinical filings for ARO-HSD, ARO-ENaC, and ARO-HIF2 around late 2019 or 2020. These were expectations, not guarantees. Janssen and Amgen control much of the clinical development and commercialization of partnered candidates, making future milestones and royalties dependent on partner decisions and program progress.
- Revenue and earnings are highly dependent on milestone timing, license accounting estimates, and collaboration activity; partner receipts and deferred revenue are not equivalent to recurring product sales or cash generated by a mature commercial business.
- All candidates remain subject to clinical, safety, regulatory, manufacturing, reimbursement, and commercialization risks. The filing emphasizes that preliminary or topline results may change after full review and may not predict later-stage outcomes.
- Other risks include dependence on third-party manufacturers and clinical research providers, intellectual-property challenges and licensing needs, competition, possible future capital needs and dilution, and exposure to interest-rate, credit, and investment-liquidity risks.
- Prior securities and derivative lawsuits relating to hepatitis B research and other public statements were reported dismissed by the filing date. The filing states there were no off-balance-sheet arrangements and no unresolved SEC staff comments.
- The auditor gave an unqualified opinion on the financial statements and internal controls. Revenue recognition was identified as a critical audit matter because estimating progress and costs to complete required significant judgment.
Key facts investors should verify
- Reconcile the $168.8 million annual revenue and FY2019 profit to the Janssen transaction, milestone recognition, deferred revenue balance, and performance-completion estimates.
- Track cash burn excluding partner payments and financing, and compare the stated 12-month liquidity assessment with actual subsequent spending and receipts.
- Review complete and updated clinical data for ARO-AAT, ARO-APOC3, ARO-ANG3, JNJ-3989, and AMG 890, including safety, durability, trial design, and endpoint results.
- Monitor clinical filing and trial timelines, R&D and manufacturing commitments, and the $60.2 million purchase-obligation estimate.
- Assess dilution and equity compensation: shares outstanding increased to 95.5 million at year-end, and 7.2 million shares were reserved for options and restricted stock units.